Ongoing challenges in drug interaction safety: From exposure to pharmacogenomics

Drug Metabolism and Pharmacokinetics

Volumn 25, Issue 1, 2010, Pages 62-71

  Bai, Jane P F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adverse events; Drug drug interactions; Intravenous drug interaction; Maximum tolerable systemic exposure; Modeling and simulation; Pharmacogenomics; Transporters

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ATORVASTATIN; BIOLOGICAL MARKER; CERIVASTATIN; CISPLATIN; CLOPIDOGREL; CYCLOSPORIN; CYTOCHROME P450 2C19; FLUINDOSTATIN; FLUOROURACIL; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MIDAZOLAM; OMEPRAZOLE; OXALIPLATIN; PITAVASTATIN; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

AREA UNDER THE CURVE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG INHIBITION; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; LUNG CANCER; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHARMACOGENETICS; PREDICTION; REVIEW; RHABDOMYOLYSIS; SIMULATION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

EID: 77949301888     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.25.62     Document Type: Review

References (39)

1. Shitara, Y., Sato, H. and Sugiyama, Y.: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol., 45: 689-723 (2005).
2. Ogihara, T., Kano, T., Wagatsuma, T., Wada, S., Yabuuchi, H., Enomoto, S., Morimoto, Shirasaka, Y., Kobayashi, S. and Tamai, I.: Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab. Dispos., 37(8):1676-1681 (2009)
3. Uno, T., Sugimoto, K., Sugawara, K. and Tateishi, T.: The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther. Drug. Monit., 30(3): 276-281 (2008).
4. Lau, T.-K., Leachman, D.-R. and Lufschanowski, R.: Severe rhab-domyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case. Tex. Heart Inst. J., 28(2): 142-145 (2001).
5. Oradell, N. J.: Physicians' Desk Reference, Medical Economics Co., 2009.
6. Neuvonen, P.-J., Niemi, M. and Backman, J.-T.: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther., 80(6): 565-581 (2006).
7. http://www.druginteractioninfo.org.
8. Tsunoda, S.-M., Velez, R.-L., von Moltke, L.-L. and Greenblatt, D.-J.: Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin. Pharmacol. Ther., 66(5): 461-471 (1999).
9. Olkkola, K.-T., Ahonen, J. and Neuvonen, P.-J.: The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth. Analg., 82(3): 511-516 (1996).
10. Chien, J.-Y., Lucksiri, A. and Ernest, C.-S. (2nd), Gorski, J.-C., Wrighton, S.-A. and Hall, S.-D.: Stochastic prediction of CY3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos., 34(7): 1208-1219 (2006).
11. Zhao, P., Ragueneau-Majlessi, I., Zhang, L., Strong, J.-M., Reynolds, K.-S., Levy, R.-H., Thummel, K.-E. and Huang, S.-M.: Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J. Clin. Pharmacol., 49(3): 351-359 (2009).
12. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.
13. Norgard, N.-B., Mathews, K.-D. and Wall, G.C.: Drug-drug in-teraction between clopidogrel and the proton pump inhibitors. Ann. Pharmacother., 43(7): 1266-1274 (2009).
14. Savi, P., Zachayus, J.-L., Delesque-Touchard, N., Labouret, C., Herve, C., Uzabiaga, M.-F., Pereillo, J. M., Culouscou, J.-M., Bono, F., Ferrara, P. and Herbert, J. M.: The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. USA, 103(29): 11069-11074 (2006).
15. Shuldiner, A.-R., O'Connell, J.-R., Bliden, K.-P., Gandhi, A., Ryan, K., Horenstein, R.-B., Damcott, C.-M., Pakyz, R., Tantry, U.-S., Gibson, Q., Pollin, T.-I., Post, W., Parsa, A., Mitchell, B.-D., Faraday, N., Herzog, W. and Gurbel, P.-A.: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302(8): 849-857 (2009).
16. Simon, T., Verstuyft, C., Mary-Krause, M., Quteinech, L., Drouet, E., Meneveau, N., Steg, P.-G., Ferrieres, J., Danchin, N. and Becquemont, L.: Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 360(4): 363-375 (2009).
17. Mega, J.-L., Close, S.-L., Wiviott, S.-D., Shen, L., Hockett, R.-D., Brandt, J.-T., Walker, J.-R., Antman, E.-M., Macias, W., Braun-wald, E. and Sabatine, M.-S.: Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 360(4): 354-362 (2009).
18. Last, E.-J. and Sheehan, A.-H.: Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors. Am. J. Health Syst. Pharm., 66(23): 2117-2122 (2009).
19. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R.: SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med., 359(8): 789-799 (2008).
20. Tirona, R.-G., Leake, B.-F., Merino, G. and Kim, R.-B.: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem., 276(38): 35669-35675 (2001).
21. Voora, D., Shah, S.-H., Spasojevic, I., Ali, S., Reed, C.-R., Salisbury, B. A. and Ginsburg, G. S.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol., 54(17): 1609-1616 (2009).
22. Tong, J., Laport, G. and Lowsky, R.: Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant., 36(8): 739-740 (2005).
23. Lasocki, A., Vote, B., Fassett, R. and Zamir, E.: Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis. Ocul. Immunol. Inflamm., 15(4): 345-346 (2007).
24. Vives, S., Batlle, M., Montane, E. and Ribera, J. M.: Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient. Med. Clin. (Barc), 131(17): 676 (2008).
25. Hirano, M., Maeda, K., Shitara, Y. and Sugiyama, Y.: Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos., 34(7): 1229-1236 (2006).
26. Hoskins, J.-M., Goldberg, R.-M., Qu, P., Ibrahim, J.-G. and McLeod, H.-L.: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst., 99(17): 1290-1295 (2007).
27. Jada, S.-R., Lim, R., Wong, C.-I., Shu, X., Lee, S.-C., Zhou, C., Goh, B.-C. and Chowbay, B.: Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421CÀA polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci, 98(9): 1461-1467 (2007).
28. Sai, K., Saito, Y., Sakamoto, H., Shirao, K., Kurose, K., Saeki, M., Ozawa, S., Kaniwa, N., Hirohashi, S., Saijo, N., Sawada, J. and Yoshida, T.: Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients. Cancer Lett., 261(2): 165-171 (2008).
29. Onoue, M, Terada, T., Kobayashi, M., Katsura, T., Matsumoto, S., Yanagihara, K., Nishimura, T., Kanai, M., Teramukai, S., Shimizu, A., Fukushima, M. and Inui, K.: UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int. J. Clin. Oncol., 14(2): 136-142 (2009).
30. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, S., Kaniwa, N., Sawada, J., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H. Kubota, K., Yoshida, T., Ohtsu, A. and Saijo, N.: Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics, 17(7): 497-504 (2007).
31. Kato, Y., Suzuki, H. and Sugiyama, Y.: Toxicological implications of hepatobiliary transpsorters. Toxicology, 181-182: 287-290 (2002).
32. Horikawa, M., Kato, Y., Tyson, C. A. and Sugiyama, Y.: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab. Pharmacokinet., 17(1): 23-33 (2002).
33. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes, E. E. and Ratain, M. J.: Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J. Clin. Oncol., 15(4): 1502-1510 (1997).
34. Desai, A.-A., Kindler, H.-L., Taber, D., Agamah, E., Mani, S., Wade-Oliver, K., Ratain, M.-J. and Vokes, E.-E.: Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer. Cancer Chemother. Pharmacol., 56(4): 421-426 (2005).
35. Fuchs, C.-S., Moore, M.-R., Harker, G., Villa, L., Rinaldi, D. and Hecht, J.-R.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J. Clin. Oncol., 21(5): 807-814 (2003).
36. Innocenti, F., Undevia, S.-D., Ramirez, J., Main, S., Schilsky, R.-L., Vogelzang, N.-Y., Prado, M. and Ratain, M.-J.: A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital. Clin. Pharmacol. Ther., 76(5): 490-502 (2004).
37. Han, J.-Y., Lim, H.-S., Shin, E.-S., Yoo, Y.-K., Park, Y.-H., Lee, J.-E., Kim, H.-T. and Lee, J.-S.: Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer, 59(1): 69-75 (2008).
38. Takane, H., Kawamoto, K., Sasaki, T., Moriki, K., Moriki, K., Kitano, H., Higuchi, S., Otsubo, K. and Ieiri, I.: Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother. Pharmacol., 63(6): 1165-1169 (2009).
39. Takane, H., Miyata, M., Burioka, N., Kurai, J., Fukuoka, Y., Suyama, H., Shigeoka, Y., Otsubo, K., Ieiri, I. and Shimizu, E.: Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug Monit., 29(5): 666-668 (2007).